ResearcherActive in the last 2 years
Antonella Venturino
Matched on ORCID iD 0000-0001-8793-8138; OpenAlex author ID A5046259040.
Their work
- Papers
- 9 (first author 0, last author 2)
- Trials
- 0
- Grants
- 0
- Collaborators
- 2
2016: 2 papers · 2017: none · 2018: 1 paper · 2019: 1 paper · 2020: 2 papers · 2021: 2 papers · 2022: none · 2023: none · 2024: none · 2025: none · 2026: 1 paper
Papers 9
- Six-month progression-free survival-related tumor growth rate after upfront chemotherapy as an outcome measure and potential prognostic or stratification varia… Last author DOI 10.1080/1120009x.2026.2717469↗
- Systemic Inflammation Scores Predict the Activity of First-Line Chemotherapy in Patients with Metastatic Pancreatic Adenocarcinoma. Co-author DOI 10.1080/07357907.2020.1863419↗
- Peripheral Blood Cell Variables Related to Systemic Inflammation in Patients With Unresectable or Metastatic Pancreatic Cancer: A Systematic Review and Meta-An… Last author DOI 10.1097/mpa.0000000000001878↗
- Tumor growth kinetics by CA 19-9 in patients with unresectable pancreatic cancer receiving chemotherapy: A retrospective analysis. Co-author DOI 10.1016/j.pan.2020.07.397↗
- Neutrophil count kinetics during the first cycle of chemotherapy predicts the outcome of patients with locally advanced or metastatic pancreatic cancer. Co-author DOI 10.1111/ajco.13325↗
- Retrospective analysis by site of primary tumor of patients with unresectable locally-advanced or metastatic pancreatic adenocarcinoma receiving chemotherapy. Co-author DOI 10.1007/s10585-019-09996-9↗
- Second-generation inflammation-related scores are more effective than systemic inflammation ratios in predicting prognosis of patients with unresectable or met… Co-author DOI 10.1007/s12032-018-1219-z↗
- CA19-9-related tumor kinetics after first-line chemotherapy of patients with advanced pancreatic cancer: a monoinstitutional experience. Co-author DOI 10.1007/s12032-016-0817-x↗
- Analysis of Response-Related and Time-to-event Endpoints in Randomized Trials of Gemcitabine-Based Treatment Versus Gemcitabine Alone as First-Line Treatment o… Co-author DOI 10.1016/j.clcc.2015.11.006↗
Closest collaborators
The 2 strongest of 2 ranked by shared papers, trials and grants, with recent and small-team work weighing most.
- Giuseppe A. Colloca · 9 shared papers, 2016–2026
- Paper Six-month progression-free survival-related tumor growth rate after upfront chemotherapy as an outcome measure and pote… DOI 10.1080/1120009x.2026.2717469↗
- Paper Peripheral Blood Cell Variables Related to Systemic Inflammation in Patients With Unresectable or Metastatic Pancreatic… DOI 10.1097/mpa.0000000000001878↗
- Paper Systemic Inflammation Scores Predict the Activity of First-Line Chemotherapy in Patients with Metastatic Pancreatic Ade… DOI 10.1080/07357907.2020.1863419↗
- Domenico Guarneri · 7 shared papers, 2016–2021
- Paper Systemic Inflammation Scores Predict the Activity of First-Line Chemotherapy in Patients with Metastatic Pancreatic Ade… DOI 10.1080/07357907.2020.1863419↗
- Paper Tumor growth kinetics by CA 19-9 in patients with unresectable pancreatic cancer receiving chemotherapy: A retrospectiv… DOI 10.1016/j.pan.2020.07.397↗
- Paper Neutrophil count kinetics during the first cycle of chemotherapy predicts the outcome of patients with locally advanced… DOI 10.1111/ajco.13325↗
How to reach this person
A chain of introductions through people who have published, run trials or held grants together (the fewest links first, then the links with the most shared work). Built from public records only; no contact details are kept.